BTIG Research Cuts Evolus (NASDAQ:EOLS) Price Target to $13.00

Evolus (NASDAQ:EOLS) had its price target dropped by investment analysts at BTIG Research from $18.00 to $13.00 in a research note issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. BTIG Research’s price objective indicates a potential upside of 165.31% from the company’s current price.

Several other research firms have also issued reports on EOLS. Stifel Nicolaus decreased their target price on Evolus from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Tuesday, January 13th. Needham & Company LLC reissued a “hold” rating on shares of Evolus in a research note on Wednesday, December 24th. Weiss Ratings restated a “sell (e+)” rating on shares of Evolus in a report on Monday, December 22nd. Wall Street Zen raised shares of Evolus from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Evolus in a report on Friday, January 9th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $19.33.

Evolus Stock Performance

EOLS opened at $4.90 on Thursday. The company has a fifty day moving average price of $6.54 and a two-hundred day moving average price of $7.07. The firm has a market capitalization of $317.62 million, a PE ratio of -5.33 and a beta of 0.91. Evolus has a 52 week low of $4.74 and a 52 week high of $17.12.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.05. The company had revenue of $68.97 million during the quarter, compared to the consensus estimate of $91.23 million. Equities analysts forecast that Evolus will post -0.61 EPS for the current year.

Insider Transactions at Evolus

In related news, insider David Moatazedi sold 10,539 shares of the stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $7.15, for a total transaction of $75,353.85. Following the completion of the sale, the insider directly owned 354,388 shares of the company’s stock, valued at approximately $2,533,874.20. This represents a 2.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 5.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in EOLS. Manchester Capital Management LLC bought a new stake in shares of Evolus during the second quarter worth $26,000. State of Alaska Department of Revenue acquired a new position in Evolus in the 3rd quarter worth $26,000. Wexford Capital LP bought a new position in Evolus during the 3rd quarter worth about $37,000. Aquatic Capital Management LLC bought a new position in Evolus during the 3rd quarter worth about $48,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Evolus in the 3rd quarter valued at about $62,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.